WO2003011892A3 - Glp-1 exendin-4 peptide analogs and uses thereof - Google Patents

Glp-1 exendin-4 peptide analogs and uses thereof Download PDF

Info

Publication number
WO2003011892A3
WO2003011892A3 PCT/US2002/024141 US0224141W WO03011892A3 WO 2003011892 A3 WO2003011892 A3 WO 2003011892A3 US 0224141 W US0224141 W US 0224141W WO 03011892 A3 WO03011892 A3 WO 03011892A3
Authority
WO
WIPO (PCT)
Prior art keywords
glp
exendin
polypeptide
relates
peptide analogs
Prior art date
Application number
PCT/US2002/024141
Other languages
French (fr)
Other versions
WO2003011892A2 (en
Inventor
Nigel H Greig
Josephine Egan
Maire Doyle
Harold Holloway
Tracy Ann Perry
Original Assignee
Us Gov Health & Human Serv
Nigel H Greig
Josephine Egan
Maire Doyle
Harold Holloway
Tracy Ann Perry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23196575&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2003011892(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CA2455963A priority Critical patent/CA2455963C/en
Priority to DE60228972T priority patent/DE60228972D1/en
Priority to JP2003517083A priority patent/JP2005501058A/en
Priority to EP02748271A priority patent/EP1411968B1/en
Priority to AU2002317599A priority patent/AU2002317599B2/en
Application filed by Us Gov Health & Human Serv, Nigel H Greig, Josephine Egan, Maire Doyle, Harold Holloway, Tracy Ann Perry filed Critical Us Gov Health & Human Serv
Priority to US10/485,140 priority patent/US7576050B2/en
Publication of WO2003011892A2 publication Critical patent/WO2003011892A2/en
Publication of WO2003011892A3 publication Critical patent/WO2003011892A3/en
Priority to AU2008202893A priority patent/AU2008202893B2/en
Priority to US12/317,042 priority patent/US8278272B2/en
Priority to US13/594,313 priority patent/US8853160B2/en
Priority to US14/470,528 priority patent/US10941187B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons

Abstract

The invention relates to novel polypeptide analogues of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or extendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogues thereof for neuroprotective and neurotrophic effects.
PCT/US2002/024141 2001-07-31 2002-07-30 Glp-1 exendin-4 peptide analogs and uses thereof WO2003011892A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
US10/485,140 US7576050B2 (en) 2001-07-31 2002-07-30 GLP-1 exendin-4 peptide analogs and uses thereof
DE60228972T DE60228972D1 (en) 2001-07-31 2002-07-30 GLP 1 EXENDIN 4 PEPTIDE ANALOG AND THEIR USES
JP2003517083A JP2005501058A (en) 2001-07-31 2002-07-30 GLP-1, EXENDIN-4, peptide analogue thereof and use thereof
EP02748271A EP1411968B1 (en) 2001-07-31 2002-07-30 Glp-1 exendin-4 peptide analogs and uses thereof
AU2002317599A AU2002317599B2 (en) 2001-07-31 2002-07-30 GLP-1 exendin-4 peptide analogs and uses thereof
CA2455963A CA2455963C (en) 2001-07-31 2002-07-30 Glp-1, exendin-4, peptide analogs and uses thereof
AU2008202893A AU2008202893B2 (en) 2001-07-31 2008-07-01 GLP-1 Exendin-4 peptide analogs and uses thereof
US12/317,042 US8278272B2 (en) 2001-07-31 2008-12-18 GLP-1, exendin-4, peptide analogs and uses thereof
US13/594,313 US8853160B2 (en) 2001-07-31 2012-08-24 GLP-1, exendin-4, peptide analogs and uses thereof
US14/470,528 US10941187B2 (en) 2001-07-31 2014-08-27 GLP-1, exendin-4, peptide analogs and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30907601P 2001-07-31 2001-07-31
US60/309,076 2001-07-31

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10485140 A-371-Of-International 2002-07-30
US10/485,140 A-371-Of-International US7576050B2 (en) 2001-07-31 2002-07-30 GLP-1 exendin-4 peptide analogs and uses thereof
US12/317,042 Continuation US8278272B2 (en) 2001-07-31 2008-12-18 GLP-1, exendin-4, peptide analogs and uses thereof

Publications (2)

Publication Number Publication Date
WO2003011892A2 WO2003011892A2 (en) 2003-02-13
WO2003011892A3 true WO2003011892A3 (en) 2004-02-26

Family

ID=23196575

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/024141 WO2003011892A2 (en) 2001-07-31 2002-07-30 Glp-1 exendin-4 peptide analogs and uses thereof

Country Status (8)

Country Link
US (4) US7576050B2 (en)
EP (3) EP2275117B1 (en)
JP (3) JP2005501058A (en)
AT (2) ATE408414T1 (en)
AU (2) AU2002317599B2 (en)
CA (1) CA2455963C (en)
DE (1) DE60228972D1 (en)
WO (1) WO2003011892A2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US8906901B2 (en) 2005-09-14 2014-12-09 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors
US8969288B2 (en) 2008-12-19 2015-03-03 Indiana University Research And Technology Corporation Amide based glucagon and superfamily peptide prodrugs
US9156902B2 (en) 2011-06-22 2015-10-13 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US9526763B2 (en) 2005-02-03 2016-12-27 Intarcia Therapeutics Inc. Solvent/polymer solutions as suspension vehicles
US9539200B2 (en) 2005-02-03 2017-01-10 Intarcia Therapeutics Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US9572889B2 (en) 2008-02-13 2017-02-21 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272652A1 (en) * 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
DE60124710T2 (en) * 2000-06-16 2007-09-13 Eli Lilly And Co., Indianapolis ANALOG OF GLUCAGON SIMILAR PEPTIDE-1
CA2455963C (en) * 2001-07-31 2017-07-04 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Glp-1, exendin-4, peptide analogs and uses thereof
DK1463751T3 (en) 2001-12-21 2013-08-26 Human Genome Sciences Inc Albumin Fusion Proteins.
CA2468700A1 (en) 2002-01-08 2003-07-17 Eli Lilly And Company Extended glucagon-like peptide-1 analogs
GB0205693D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
PL1605897T3 (en) * 2003-03-19 2012-12-31 Lilly Co Eli Polyethelene glycol link glp-1 compounds
AU2004240630B2 (en) * 2003-05-15 2010-10-07 Trustees Of Tufts College Stable analogs of peptide and polypeptide therapeutics
US7329725B1 (en) * 2003-10-29 2008-02-12 Nastech Pharmaceutical Company Inc. Phage displayed Trp cage ligands
US7538185B2 (en) 2004-01-08 2009-05-26 Theratechnologies Inc. Glucagon-like peptide-1 analogs with long duration of action
JP5638177B2 (en) 2004-02-11 2014-12-10 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc Pancreatic polypeptide family motif and polypeptide containing the motif
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
US7893017B2 (en) 2004-10-07 2011-02-22 Novo Nordisk A/S Protracted GLP-1 compounds
US8030273B2 (en) 2004-10-07 2011-10-04 Novo Nordisk A/S Protracted exendin-4 compounds
US20070021336A1 (en) * 2004-12-24 2007-01-25 Christen Anderson Use of GLP-1 and agonists thereof to prevent cardiac myocyte apoptosis
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
EP2390264A1 (en) 2005-02-11 2011-11-30 Amylin Pharmaceuticals Inc. GIP analog and hybrid polypeptides with selectable propperties
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
CA2606894A1 (en) * 2005-05-05 2007-02-15 Cadila Healthcare Limited Novel compounds as glp-i agonists
CN100429227C (en) 2005-06-29 2008-10-29 常州制药厂有限公司 Exendin 4 polypeptide segment
MX2008002028A (en) * 2005-08-11 2008-03-27 Amylin Pharmaceuticals Inc Hybrid polypeptides with selectable properties.
AU2006279680B2 (en) * 2005-08-11 2012-12-06 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
CA2623412A1 (en) * 2005-09-08 2007-03-15 Uutech Limited Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function
EP2497781A1 (en) * 2005-09-08 2012-09-12 Trustees Of Tufts College Stabilized GLP-1 analogs
CA2622069A1 (en) * 2005-09-08 2007-03-15 Uutech Limited Treatment of diabetes related obesity
CA2622642C (en) 2005-09-16 2013-12-31 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
SI1767545T1 (en) 2005-09-22 2010-03-31 Biocompatibles Uk Ltd GLP-1 (Glucagon-like peptide-1) fusion polypeptides with increased peptidase resistance
ES2572952T3 (en) 2005-11-07 2016-06-03 Indiana University Research And Technology Corporation Glucagon analogs showing physiological solubility and stability
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP2004213A1 (en) * 2006-04-03 2008-12-24 Novo Nordisk A/S Glp-1 peptide agonists
US8288339B2 (en) * 2006-04-20 2012-10-16 Amgen Inc. GLP-1 compounds
ATE444741T1 (en) 2006-05-10 2009-10-15 Biocompatibles Uk Ltd Spherical microcapsules containing GLP-1 peptides, their production and their use
CN102274557B (en) 2006-08-09 2014-12-03 精达制药公司 Osmotic delivery systems and piston assemblies
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
CN101578102B (en) 2007-01-05 2013-07-17 印第安纳大学研究及科技有限公司 Glucagon analogs exhibiting enhanced solubility in physiological pH buffers
RU2413528C2 (en) 2007-01-18 2011-03-10 Открытое Акционерное Общество "Валента Фармацевтика" Exenatide and dalargin drug for treating diabetes, adminisration and therapy
EP2487184A1 (en) 2007-02-15 2012-08-15 Indiana University Research and Technology Corporation Glucagon/GLP-1 receptor co-agonists
EP1972349A1 (en) * 2007-03-21 2008-09-24 Biocompatibles UK Limited GLP-1 fusion peptides conjugated to polymer(s), their production and use
EP1975176A1 (en) * 2007-03-27 2008-10-01 Biocompatibles UK Limited Novel glp-1 fusion peptides, their production and use
NZ580447A (en) 2007-04-23 2011-06-30 Intarcia Therapeutics Inc Suspension formulations of insulinotropic peptides and uses thereof
WO2009030771A1 (en) * 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
WO2009030774A1 (en) * 2007-09-05 2009-03-12 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
JP5476304B2 (en) 2007-09-05 2014-04-23 ノボ・ノルデイスク・エー／エス Glucagon-like peptide-1 derivatives and their pharmaceutical use
GB0717399D0 (en) 2007-09-07 2007-10-17 Uutech Ltd Use of GLP-1 analogues for the treatment of disorders associated with dysfunctional synaptic transmission
GB0717388D0 (en) 2007-09-07 2007-10-17 Uutech Ltd Use of GIP for the treatment of disorders associated with dysfunctional synaptic transmission
AU2008318876B2 (en) 2007-10-30 2014-05-15 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and GLP-1 agonist activity
WO2009058662A2 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Glucagon antagonists
US20110245173A1 (en) * 2008-06-03 2011-10-06 Bachovchin William W Long-Acting GLP-1 Derivatives, and Methods of Treating Cardiac Dysfunction
CA2727161A1 (en) 2008-06-17 2009-12-23 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers
TWI474832B (en) 2008-06-17 2015-03-01 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
EP2952202B1 (en) 2008-06-17 2017-10-18 Indiana University Research and Technology Corporation Gip-based mixed agonists for treatment of metabolic disorders and obesity
WO2010043566A2 (en) 2008-10-17 2010-04-22 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a glp-1 agonist
EP2384338A4 (en) * 2008-12-29 2013-01-16 Panacea Biotec Ltd Glp-1 analogs and uses thereof
WO2010120476A2 (en) * 2009-04-01 2010-10-21 Amylin Pharmaceuticals, Inc. N-terminus conformationally constrained glp-1 receptor agonist compounds
US8992886B2 (en) * 2009-04-06 2015-03-31 Board Of Regents, The University Of Texas System Cyclic peptide analogues for non-invasive imaging of pancreatic beta-cells
US9150632B2 (en) 2009-06-16 2015-10-06 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
US20120148586A1 (en) * 2009-08-27 2012-06-14 Joyce Ching Tsu Chou Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
CA2775676C (en) 2009-09-28 2016-08-16 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
AU2010317994B2 (en) 2009-11-13 2014-03-06 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist and methionine
PL2498802T3 (en) 2009-11-13 2015-06-30 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist, an insulin, and methionine
EP2512503A4 (en) 2009-12-18 2013-08-21 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
MX2012008603A (en) 2010-01-27 2013-01-25 Univ Indiana Res & Tech Corp Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity.
MX2012013001A (en) 2010-05-13 2013-02-26 Univ Indiana Res & Tech Corp Glucagon superfamily peptides exhibiting nuclear hormone receptor activity.
BR112012028707A2 (en) 2010-05-13 2019-09-24 Univ Indiana Res & Tech Corp glucagon compound of the peptide superfamily exhibiting g receptor activity with coupled protein, prodrug, dimer or multimer, pharmaceutical composition comprising it and method of administration thereof.
CA2796894A1 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
AU2010360116B2 (en) 2010-08-30 2014-06-26 Sanofi-Aventis Deutschland Gmbh Use of AVE0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US9023986B2 (en) 2010-10-25 2015-05-05 Hoffmann-La Roche Inc. Glucose-dependent insulinotropic peptide analogs
MX345501B (en) 2010-12-16 2017-02-02 Novo Nordisk As Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid.
CA2821766A1 (en) 2010-12-22 2012-06-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
US9050347B2 (en) 2011-01-25 2015-06-09 Viviabiotech, S.L. 1,2,4-oxadiazole derivatives as drugs modulating the GLP-1 peptide receptor
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN106117343B (en) 2011-04-12 2020-11-03 诺沃—诺迪斯克有限公司 Double acylated GLP-1 derivatives
CA2833623A1 (en) 2011-04-20 2012-10-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Aav mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
WO2012177444A2 (en) 2011-06-22 2012-12-27 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
WO2013030160A1 (en) 2011-08-29 2013-03-07 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
AR087744A1 (en) * 2011-09-01 2014-04-16 Sanofi Aventis Deutschland PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE
KR20140097151A (en) 2011-11-17 2014-08-06 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
US9388212B2 (en) 2013-02-21 2016-07-12 Chemical & Biopharmaceutical Laboratories Of Patras S.A. Solid phase peptide synthesis via side chain attachment
US10933120B2 (en) 2012-03-22 2021-03-02 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
HUE042757T2 (en) 2012-03-22 2019-07-29 Novo Nordisk As Compositions comprising a delivery agent and preparation thereof
CN104487056A (en) 2012-06-20 2015-04-01 诺和诺德A/S（股份有限公司） Tablet formulation comprising a peptide and a delivery agent
AR091477A1 (en) 2012-06-21 2015-02-04 Univ Indiana Res & Tech Corp GLUCAGON ANALOGS PRESENTING GIP RECEIVER ACTIVITY
UA116217C2 (en) 2012-10-09 2018-02-26 Санофі Exendin-4 derivatives as dual glp1/glucagon agonists
EP2928562A4 (en) * 2012-12-06 2016-06-22 Stealth Peptides Int Inc Peptide therapeutics and methods for using same
EP2935318A1 (en) * 2012-12-19 2015-10-28 Novo Nordisk A/S Novel glp-1 receptor agonists with cholesterol efflux activity
RU2015129788A (en) 2012-12-21 2017-01-30 Санофи EXENDIN-4 DERIVATIVES AS GLP1 / GIP DOUBLE AGONISTS OR GLP1 / GIP / GLUCAGON TRIPLE ANGONISTS
JP6382488B2 (en) * 2013-02-21 2018-08-29 ケミカル アンド バイオファーマシューティカル ラボラトリーズ オブ パトラ エス．エー． Solid phase peptide synthesis via side chain bonds
CA2929555A1 (en) 2013-11-08 2015-05-14 Baylor Research Institute Nuclear localization of glp-1 stimulates myocardial regeneration and reverses heart failure
CN105934257B (en) 2013-12-06 2020-10-09 韩捷 Bioreversible introducing group for nitrogen and hydroxyl-containing drugs
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
TW201609795A (en) 2013-12-13 2016-03-16 賽諾菲公司 EXENDIN-4 peptide analogues as dual GLP-1/GIP receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
TW201625670A (en) 2014-04-07 2016-07-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
TW201625668A (en) 2014-04-07 2016-07-16 賽諾菲公司 Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
TW201625669A (en) 2014-04-07 2016-07-16 賽諾菲公司 Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
GB201415598D0 (en) 2014-09-03 2014-10-15 Univ Birmingham Elavated Itercranial Pressure Treatment
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
HUE062573T2 (en) 2014-12-12 2023-11-28 Sanofi Aventis Deutschland Insulin glargine/lixisenatide fixed ratio formulation
EA035527B1 (en) 2014-12-30 2020-06-30 Ханми Фарм. Ко., Лтд. Glucagon derivatives with improved stability
TWI748945B (en) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 Treatment type 2 diabetes mellitus patients
TW201705975A (en) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment of type 2 diabetes mellitus patients
US10993993B2 (en) 2015-05-28 2021-05-04 Immunoforge Co., Ltd. Pharmaceutical composition for treating muscle atrophy or sarcopenia including glucagon-like peptide (GLP-1) or GLP-1 receptor agonist
KR101661332B1 (en) * 2015-05-28 2016-09-29 (의료)길의료재단 Pharmaceutical composition for treating muscle atrophy comprising glucagon like-peptide-1 receptor agonist
CN113598842A (en) 2015-06-03 2021-11-05 因塔西亚制药公司 Implant placement and removal system
AR105319A1 (en) 2015-06-05 2017-09-27 Sanofi Sa PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR
AR105485A1 (en) 2015-06-30 2017-10-11 Hanmi Pharm Ind Co Ltd DERIVATIVE OF GLUCAGÓN AND A COMPOSITION THAT INCLUDES A CONJUGATE OF PROLONGED ACTION OF THE SAME
TW201706291A (en) 2015-07-10 2017-02-16 賽諾菲公司 New EXENDIN-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists
CN108697768B (en) * 2015-12-23 2022-07-22 约翰霍普金斯大学 Long-acting GLP-1R agonists as methods of treatment for neurological and neurodegenerative conditions
CA3010265A1 (en) 2015-12-31 2017-07-06 Hanmi Pharm. Co., Ltd. Long-acting conjugate of triple glucagon/glp-1/gip receptor agonist
EP3458084B1 (en) 2016-05-16 2020-04-01 Intarcia Therapeutics, Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
CA3029518A1 (en) 2016-06-29 2018-01-04 Hanmi Pharm. Co., Ltd. Glucagon derivative, conjugate thereof, composition comprising same, and therapeutic use thereof
KR20210092335A (en) 2016-10-20 2021-07-23 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 The method for delivering the neuroprotection polypeptide to the central nervous system
KR20190104039A (en) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Methods Including Continuous Administration of GLP-1 Receptor Agonists and Co-administration of Drugs
BR112020014624A2 (en) 2018-02-02 2020-12-08 Novo Nordisk A/S SOLID COMPOSITIONS UNDERSTANDING GLP-1 AGONIST, CAPRILIC AND LUBRICANT N- (8- (2-HYDROXYBENZOIL) AMINO ACID SALT)
CN110452952B (en) * 2018-05-08 2024-01-16 宜昌东阳光长江药业股份有限公司 Method for detecting bioactivity of GLP-1 analogue
KR101921085B1 (en) 2018-05-21 2018-11-22 이뮤노포지 주식회사 Pharmaceutical composition for treating muscle atrophy comprising glucagon like-peptide-1, GLP-1 derived peptide, or GLP-1 degradation inhibitor
KR102119188B1 (en) * 2018-11-13 2020-06-08 이뮤노포지 주식회사 Pharmaceutical composition for treating muscle atrophy comprising glucagon like-peptide-1, GLP-1 derived peptide, or GLP-1 degradation inhibitor
WO2020175570A1 (en) * 2019-02-28 2020-09-03 新田ゼラチン株式会社 Brain function regulator, and food or beverage containing same
WO2020214012A1 (en) * 2019-04-19 2020-10-22 한미약품 주식회사 Preventive or therapeutic pharmaceutical composition for hyperlipidemia comprising triple agonist acting on all of glucagon, glp-1 and gip receptors, or conjugate thereof, and preventive or therapeutic method
WO2020214013A1 (en) * 2019-04-19 2020-10-22 한미약품 주식회사 Therapeutic use, for hyperlipideamia, of triple agonist having activity with respect to all of glucagon, glp-1, and gip receptors, or conjugate thereof
CN114599665A (en) 2019-08-16 2022-06-07 应用分子转运公司 Compositions, formulations and interleukin production and purification
IL294631A (en) * 2020-01-13 2022-09-01 Hanmi Pharm Ind Co Ltd Therapeutic use of longacting conjugate of triple agonist having activities to all of glucagon/glp-1/gip receptors for lung disease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998030231A1 (en) * 1997-01-07 1998-07-16 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
WO1999040788A1 (en) * 1998-02-13 1999-08-19 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and glp-1
WO2000016797A2 (en) * 1998-09-24 2000-03-30 Eli Lilly And Company Use of glp-1 or analogs in treatment of stroke
US6429197B1 (en) * 1998-10-08 2002-08-06 Bionebraska, Inc. Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
EP0658568A1 (en) 1993-12-09 1995-06-21 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
GB9409496D0 (en) 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US5574008A (en) * 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
EP0915910B1 (en) 1996-06-05 2006-01-18 Roche Diagnostics GmbH Exendin analogues, processes for their preparation and medicaments containing them
US6268479B1 (en) * 1997-03-12 2001-07-31 The Trustees Of Columbia University In The City Of New York Intracellular amyloid-beta peptide binding (ERAB) polypeptide
EP1052994A2 (en) 1998-02-02 2000-11-22 Trustees Of Tufts College Use of dipeptidylpetidase inhibitors to regulate glucose metabolism
JP2002508162A (en) 1998-02-27 2002-03-19 ノボ ノルディスク アクティーゼルスカブ GLP-1 derivative with shortened N-terminus
EP1062229A1 (en) 1998-03-09 2000-12-27 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
DE19828113A1 (en) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs of Dipeptidyl Peptidase IV Inhibitors
AU776514B2 (en) 1998-08-10 2004-09-09 General Hospital Corporation, The Differentiation of non-insulin producing cells into insulin producing cells by GLP-1 or exendin-4 and uses thereof
JP2002538081A (en) 1998-12-07 2002-11-12 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス Analogs of GLP-1
BR9915961A (en) 1998-12-07 2001-08-21 Sod Conseils Rech Applic Glp-1 analogs
JP3136356B2 (en) 1998-12-15 2001-02-19 農林水産省家畜衛生試験場長 DNA encoding modified signal peptide
EP1140145B2 (en) * 1999-01-14 2019-05-15 Amylin Pharmaceuticals, LLC Novel exendin agonist formulations and methods of administration thereof
JP2003518914A (en) 1999-02-10 2003-06-17 キュリス インコーポレイテッド Methods and reagents for treating glucose metabolism disorders
CN1191273C (en) * 1999-05-17 2005-03-02 康久化学公司 Long lasting insulinotropic peptides
US6506724B1 (en) * 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
EP1076066A1 (en) * 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
CN1423566A (en) 1999-11-10 2003-06-11 武田药品工业株式会社 Body weight gain inhibitor
US6278018B1 (en) 1999-12-14 2001-08-21 Surmodics, Inc. Surface coating agents
ES2227115T5 (en) 2000-01-10 2014-10-30 Amylin Pharmaceuticals, Inc. Use of exendins and their agonists for the treatment of hypertriglyceridemia
WO2001060411A1 (en) * 2000-02-18 2001-08-23 Kanagawa Academy Of Science And Technology Pharmaceutical composition, reagent and method for intracerebral delivery of pharmaceutically active ingredient or labeling substance
EP1136071A3 (en) * 2000-03-22 2003-03-26 Pfizer Products Inc. Use of glycogen phosphorylase inhibitors
US20020115605A1 (en) * 2000-08-24 2002-08-22 Matthew During Novel peptide with effects on cerebral health
SI1724284T1 (en) * 2000-12-07 2009-12-31 Lilly Co Eli GLP-1 fusion proteins
CA2455963C (en) 2001-07-31 2017-07-04 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Glp-1, exendin-4, peptide analogs and uses thereof
EP1532261B1 (en) * 2002-05-24 2010-02-10 Medtronic, Inc. Methods and dna constructs for high yield production of polypeptides
US6969702B2 (en) * 2002-11-20 2005-11-29 Neuronova Ab Compounds and methods for increasing neurogenesis
DOP2006000008A (en) * 2005-01-10 2006-08-31 Arena Pharm Inc COMBINED THERAPY FOR THE TREATMENT OF DIABETES AND RELATED AFFECTIONS AND FOR THE TREATMENT OF AFFECTIONS THAT IMPROVE THROUGH AN INCREASE IN THE BLOOD CONCENTRATION OF GLP-1
EP1940454A4 (en) 2005-09-28 2012-01-04 Ventria Bioscience Oral formulation for enteric disorders and/or rehydration
JP2013007734A (en) 2011-01-17 2013-01-10 Nippon Dempa Kogyo Co Ltd External force detection device and external force detection sensor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998030231A1 (en) * 1997-01-07 1998-07-16 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
WO1999040788A1 (en) * 1998-02-13 1999-08-19 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and glp-1
WO2000016797A2 (en) * 1998-09-24 2000-03-30 Eli Lilly And Company Use of glp-1 or analogs in treatment of stroke
US6429197B1 (en) * 1998-10-08 2002-08-06 Bionebraska, Inc. Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AHREN ET AL.: "No correlation between insulin and islet amyloid polypeptide after stimulation with glucagon-like peptide-1 in type 2 diabetes", EUROPEAN JOURNAL OF ENDOCRINOLOGY, vol. 137, 1997, pages 643 - 649, XP002969805 *
DOYLE ET AL.: "Insertion of an N-terminal 6-aminohexanoic acid after the 7 amino acid position of glucagon-like peptide-1 produces a long-acting hypoglycemic agent", ENDOCRINOLOGY, vol. 142, no. 10, 2001, pages 4462 - 4468, XP002969806 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9526763B2 (en) 2005-02-03 2016-12-27 Intarcia Therapeutics Inc. Solvent/polymer solutions as suspension vehicles
US9539200B2 (en) 2005-02-03 2017-01-10 Intarcia Therapeutics Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US8906901B2 (en) 2005-09-14 2014-12-09 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US9572889B2 (en) 2008-02-13 2017-02-21 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US8969288B2 (en) 2008-12-19 2015-03-03 Indiana University Research And Technology Corporation Amide based glucagon and superfamily peptide prodrugs
US9156902B2 (en) 2011-06-22 2015-10-13 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists

Also Published As

Publication number Publication date
AU2002317599B2 (en) 2008-04-03
CA2455963A1 (en) 2003-02-13
EP1411968A4 (en) 2005-06-15
JP2013139447A (en) 2013-07-18
US8853160B2 (en) 2014-10-07
US10941187B2 (en) 2021-03-09
US20040242853A1 (en) 2004-12-02
EP2275117A1 (en) 2011-01-19
AU2008202893B2 (en) 2012-01-12
EP1411968A2 (en) 2004-04-28
ATE536881T1 (en) 2011-12-15
EP2022505A2 (en) 2009-02-11
US20090253625A1 (en) 2009-10-08
CA2455963C (en) 2017-07-04
DE60228972D1 (en) 2008-10-30
AU2008202893A1 (en) 2008-07-24
US20150072930A1 (en) 2015-03-12
US8278272B2 (en) 2012-10-02
EP2275117B1 (en) 2016-10-26
EP1411968B1 (en) 2008-09-17
US20120329715A1 (en) 2012-12-27
ATE408414T1 (en) 2008-10-15
JP5631578B2 (en) 2014-11-26
EP2022505B1 (en) 2011-12-14
US7576050B2 (en) 2009-08-18
EP2022505A3 (en) 2009-05-27
JP2010090129A (en) 2010-04-22
JP5695097B2 (en) 2015-04-01
JP2005501058A (en) 2005-01-13
WO2003011892A2 (en) 2003-02-13

Similar Documents

Publication Publication Date Title
WO2003011892A3 (en) Glp-1 exendin-4 peptide analogs and uses thereof
EP0997151A3 (en) Method for administering insulinotropic peptides
WO2003053339A3 (en) Insulin molecule having protracted time action
WO2006024275A3 (en) Glp-1 and exendin related invention
EP0951910A3 (en) Method for administering monomeric insulin analogs
ZA200606153B (en) Intranasal administration of glucose-regulating peptides
WO2003018516A3 (en) Glucagon-like peptide-1 analogs
WO1999043705A8 (en) N-terminally truncated glp-1 derivatives
ATE251642T1 (en) BIOLOGICALLY ACTIVE FRAGMENTS OF GLUCAGON-LIKE INSULINOTROPIC PEPTIDES
MXPA01009805A (en) Peptide.
WO2005000222A3 (en) Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
WO2002048192A3 (en) Amidated glucagon-like peptide-1
HUP0100928A3 (en) Methods for treatment of diabetes using peptide analogues of insulin
DK1294757T3 (en) Glucagon-like peptide 1 analogues
AU2002213925A1 (en) Use of glp-1 and flp-2 peptides for treatment of bone disorders
HK1070589A1 (en) Prolanged delivery of peptides
WO2004100968A3 (en) A synergistic composition for the treatment of diabetes mellitus
AU2003234529A8 (en) Glp-1 gene delivery for the treatment of type 2 diabetes
AU2689702A (en) Glp-1 fusion proteins
CY1110287T1 (en) USE OF HUMAN PARATHYROID HORMONES
WO2004111078A3 (en) Compounds that modulate the glucagon response and uses thereof
WO2002038129A3 (en) Delayed-release pharmaceutical formulations containing proinsulin c-peptide
HUP0202755A3 (en) C-peptide for the improved production of insulin and insulin analogues
WO2005117584A3 (en) Improved transmucosal delivery of peptides and proteins
HUP0400464A3 (en) Adenosine analogues for treatment of the insulin resistance syndrome and diabetes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CR CU CZ DE DK DZ EE ES FI GB GD GE GH GM HR ID IL IN IS JP KE KG KP KR KZ LC LR LS LT LU LV MA MD MG MK MN MX MZ NO NZ PL PT RO RU SD SE SG SK SL TJ TM TR TT TZ UA UG US UZ YU ZA

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2455963

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003517083

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002748271

Country of ref document: EP

Ref document number: 2002317599

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 10485140

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2002748271

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642